All In Biotech

NDA 216873 · Glaxosmithkline

Ojjaara

Momelotinib Dihydrochloride · Oral

NovelOrphan

CDER novel approval, Sep 15, 2023: To treat intermediate or high-risk myelofibrosis in adults with anemia

Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Sep 15, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

0

0 Phase 3, 0 recruiting

FAERS reports

1,481

978 serious, 230 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 20, 2026.

OJJAARA is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia. OJJAARA is a kinase inhibitor indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia. ( 1 )

Mechanism: Momelotinib is an inhibitor of wild type Janus Kinase 1 and 2 (JAK1/JAK2) and mutant JAK2 V617F , which contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Momelotinib and its major human circulating metabolite, M21, have higher inhibitory activity for JAK2 compared to JAK3 and tyrosine kinase 2 (TYK2). Momelotinib and M21 additionally inhibit activin A receptor type 1 (ACVR1), also known as activin receptor like kinase 2 (ALK2), which produces subsequent inhibition of liver hepcidin expression and increased iron...

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 15, 2023 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
3 products under this application
  • OJJAARA · MOMELOTINIB DIHYDROCHLORIDE EQ 200MG BASE · TABLET, ORAL · Prescription
  • OJJAARA · MOMELOTINIB DIHYDROCHLORIDE EQ 100MG BASE · TABLET, ORAL · Prescription
  • OJJAARA · MOMELOTINIB DIHYDROCHLORIDE EQ 150MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Momelotinib Dihydrochloride" as an intervention, any sponsor and status, largest first.

All 0 trials

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death113
  • thrombocytopenia112
  • myelofibrosis96
  • drug ineffective90
  • anaemia86
  • diarrhoea78
  • pneumonia74
  • fatigue72
  • haemoglobin decreased66
  • dizziness63
  • hospitalisation63
  • platelet count decreased62

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20151
20162
20175
20183
20194
20201
20212
20225
202367
2024381
2025580
2026430

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ojjaara (Momelotinib Dihydrochloride)

2024 spending

$342M

Beneficiaries

2,316

12,239 claims

Per beneficiary

$147,536

$912.19 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$27,017,098
2024$341,692,382

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.